Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Tutt

Showing results (71-80 of 91) with videos related to

Pageof 10
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2009
Tiling path genomic profiling of grade 3 invasive ductal breast cancersRachael Natrajan, Maryou B Lambros, Socorro María Rodríguez-Pinilla, et al.
Oncogene|April 19, 2022
Loss of E-cadherin leads to Id2-dependent inhibition of cell cycle progression in metastatic lobular breast cancerMax A K Rätze, Thijs Koorman, Thijmen Sijnesael, et al.
Oncogene|May 24, 2022
Correction: Loss of E-cadherin leads to Id2-dependent inhibition of cell cycle progression in metastatic lobular breast cancerMax A K Rätze, Thijs Koorman, Thijmen Sijnesael, et al.
NPJ Breast Cancer|January 24, 2025
Unraveling complexity and leveraging opportunities in uncommon breast cancer subtypesFresia Pareja, Rohit Bhargava, Virginia F Borges, et al.
Cancer Cell|August 16, 2017
Genomic Evolution of Breast Cancer Metastasis and RelapseLucy R Yates, Stian Knappskog, David Wedge, et al.
Trials|September 6, 2022
Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials unitsSharon B Love, Fay Cafferty, Claire Snowdon, et al.
Science Signaling|August 21, 2014
The ErbB4 CYT2 variant protects EGFR from ligand-induced degradation to enhance cancer cell motilityTai Kiuchi, Elena Ortiz-Zapater, James Monypenny, et al.
NPJ Breast Cancer|May 22, 2020
Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trialsJan Hudeček, Leonie Voorwerk, Maartje van Seijen, et al.
Nature Medicine|May 2, 2018
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT TrialAndrew Tutt, Holly Tovey, Maggie Chon U Cheang, et al.
Nature Medicine|March 14, 2017
HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signaturesHelen Davies, Dominik Glodzik, Sandro Morganella, et al.
Pageof 10

Showing results (71-80 of 91) with videos related to

Sort By:
Pageof 10
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2009
Tiling path genomic profiling of grade 3 invasive ductal breast cancersRachael Natrajan, Maryou B Lambros, Socorro María Rodríguez-Pinilla, et al.
Oncogene|April 19, 2022
Loss of E-cadherin leads to Id2-dependent inhibition of cell cycle progression in metastatic lobular breast cancerMax A K Rätze, Thijs Koorman, Thijmen Sijnesael, et al.
Oncogene|May 24, 2022
Correction: Loss of E-cadherin leads to Id2-dependent inhibition of cell cycle progression in metastatic lobular breast cancerMax A K Rätze, Thijs Koorman, Thijmen Sijnesael, et al.
NPJ Breast Cancer|January 24, 2025
Unraveling complexity and leveraging opportunities in uncommon breast cancer subtypesFresia Pareja, Rohit Bhargava, Virginia F Borges, et al.
Cancer Cell|August 16, 2017
Genomic Evolution of Breast Cancer Metastasis and RelapseLucy R Yates, Stian Knappskog, David Wedge, et al.
Trials|September 6, 2022
Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials unitsSharon B Love, Fay Cafferty, Claire Snowdon, et al.
Science Signaling|August 21, 2014
The ErbB4 CYT2 variant protects EGFR from ligand-induced degradation to enhance cancer cell motilityTai Kiuchi, Elena Ortiz-Zapater, James Monypenny, et al.
NPJ Breast Cancer|May 22, 2020
Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trialsJan Hudeček, Leonie Voorwerk, Maartje van Seijen, et al.
Nature Medicine|May 2, 2018
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT TrialAndrew Tutt, Holly Tovey, Maggie Chon U Cheang, et al.
Nature Medicine|March 14, 2017
HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signaturesHelen Davies, Dominik Glodzik, Sandro Morganella, et al.
Pageof 10